Abstract:Normalizing the tumor‐induced immune deficiency in the immunosuppressive tumor microenvironment (TME) through increasing the efficient infiltration and activation of antitumoral immunity in TME is the core of promising immunotherapy. Herein, a Cyclo(Arg‐Gly‐Asp‐d‐Phe‐Lys) (RGD) peptides‐modified combinatorial immunotherapy system based on the self‐assembly of the nanoparticles named RGD‐DMA composed of RGD‐PEG‐PLA, methoxy poly(ethylene glycol)‐poly(lactide) (MPEG‐PLA) and 1,2‐Dioleoyl‐3‐trimethylammonium‐propane (DOTAP) is used to codeliver the immunostimulatory chemokine CCL19‐encoding plasmid DNA (CCL19 pDNA) and immune checkpoint ligand PD‐L1 inhibitor (BMS‐1). The RGD‐DMA/pCCL19‐BMS‐1 system not only exhibited significant inhibition of tumor progression but also induced locally high concentrations of immunostimulatory cytokines at tumor sites without causing an obviously systemic inflammatory response. The immunosuppressive TME is efficaciously reshaped by the coadministration of RGD‐DMA/pCCL19 and BMS‐1, as indicated by the activated T lymphocytes, increased intratumoral‐infiltration of mature dendritic cells (DCs), and the repolarization of macrophages from pro‐tumoral M2‐phenotype toward tumoricidal M1‐phenotype. The upregulated PD‐L1 expression at tumor sites caused by the increased IFN‐γ levels after immunostimulatory gene therapy further demonstrated the synergistic effects of BMS‐1 in counteracting the inhibitory role of PD‐L1 expression in antitumor immunity. Therefore, the combination of immunostimulating therapy and immune checkpoint inhibitor that synergistically target multiple immune regulatory pathways demonstrates significant potential as a novel immunotherapy approach. The combined immunotherapy by RGD‐DMA nanoparticles delivering pDNA encoding the immunostimulating chemokine CCL19 with immune checkpoint small molecular inhibitor BMS‐1 synergistically targets multiple immune regulatory pathways, as indicated by inducing the activation of lymphocytes, repolarizing tumor‐associated macrophages toward a tumoricidal M1 phenotype as well as promoting the maturation of tumor‐infiltrating dendritic cells in the tumor microenvironment (TME). The codelivery of CCL19 plasmid DNA and BMS‐1 by RGD‐DMA significantly reshapes the immunosuppressive TME and leads to a strong antitumor effect.

Combination of Epigenetic Regulation with Gene Therapy-Mediated Immune Checkpoint Blockade Induces Anti-Tumour Effects and Immune Response in Vivo.

Multifunctional Metal Complex-Based Gene Delivery for Tumour Immune Checkpoint Blockade Combination Therapy

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation

In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy

Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.

Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors

Nano‐Regulator Inhibits Tumor Immune Escape via the "Two‐Way Regulation" Epigenetic Therapy Strategy

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

Strategies of Combination Drug Delivery for Immune Checkpoint Blockades.

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

Reversing EZH2‐Mediated Epigenetic Silence with Photodynamic Polymeric Nanoparticles for Synergistically Enhanced Antitumor Immunotherapy

Unlocking PD‐1 antibody resistance: The MUC1 DNA vaccine augments CD8+ T cell infiltration and attenuates tumour suppression

In Situ Editing of Tumour Cell Membranes Induces Aggregation and Capture of PD-L1 Membrane Proteins for Enhanced Cancer Immunotherapy

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Disrupting Tumour Vasculature and Recruitment of Apdl1-Loaded Platelets Control Tumour Metastasis

Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity Against Advanced Cancer

Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer

Combination of AAV-delivered Tumor Suppressor PTEN with Anti-Pd-1 Loaded Depot Gel for Enhanced Antitumor Immunity

Reversing Immune Suppression and Potentiating Photothermal Immunotherapy Via Bispecific Immune Checkpoint Inhibitor Loaded Hollow Polydopamine Nanospheres